Silver-NanoParticles / selectivity Cancer Research Results

AgNPs, Silver-NanoParticles: Click to Expand ⟱
Features:
Silver NanoParticles (AgNPs)
Summary:
1.Smaller sizes are generally more bioactive due to increased surface area and enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect.
2.Two relevant forms: particulate silver (AgNPs) and ionic silver (Ag⁺). There is debate regarding oral use, as Ag⁺ can precipitate as AgCl in gastric acid, reducing bioavailability; AgNPs may partially avoid this via particulate uptake and intracellular Ag⁺ release. Gastric pH may influence this equilibrium.
3. Dose example 80kg person: 1.12-2mg/day, which can be calculated based on ppm and volume taken (see below) target < 10ppm and 120mL per day (30ppm and 1L per day caused argyria 30mg/day ) (Case Report: 9‐15 ppm@120mL, i.e. 1.1mg/L to 1.8mg/L per day)
Likely 10ppm --> 10mg/L, hence if take 100mL, then 1mg/day? (for Cancer)
The current Rfd for oral silver exposure is 5 ug/kg/d with a critical dose estimated at 14 ug/kg/d for the average person.
Seems like the Cancer target range is 14ug/kg/day to 25ug/kg/day. 80Kg example: 1.12mg to 2mg “1.4µg/kg body weight. If I would have 70kg, I would want to use 100µg/day. However, for fighting active disease, I would tend to explore higher daily dose, as I think this may be too low.”
These values reflect experimental or anecdotal contexts and are not established safe or therapeutic doses.
4. Antioxidants such as NAC can counteract AgNP cytotoxicity by restoring glutathione pools and suppressing ROS-mediated mitochondrial damage.
5. In vitro studies commonly show ROS elevation in both cancer and normal cells; however, in vivo, superior antioxidant, NRF2, and repair capacity in normal tissues may confer selectivity.
6. Pathways/mechanisms of action/:
-” intracellular ROS was increased...reduction in levels of glutathione (GSH)”
- Normal-cell selectivity is partly mediated by NRF2-dependent antioxidant and detoxification responses.
- AgNPs impair mitochondrial electron transport, increasing electron leak and amplifying ROS upstream of ΔΨm collapse.
-AgNPs inhibit VEGF-driven endothelial signaling and permeability (anti-angiogenic effect)
-”upregulation of proapoptotic genes (p53, p21, Bax, and caspases) and downregulation of antiapoptotic genes (Bcl-2)”
-” upregulation of AMPK and downregulation of mTOR, MMP-9, BCL-2, and α-SMA”
-”p53 is a key player...proapoptotic genes p53 and Bax were significantly increased... noticeable reduction in Bcl-2 transcript levels”
-” p53 participates directly in the intrinsic apoptosis pathway by regulating the mitochondrial outer membrane permeabilization”
- “Proapoptotic markers (BAX/BCL-XL, cleaved poly(ADP-ribose) polymerase, p53, p21, and caspases 3, 8 and 9) increased.”
-”The antiapoptotic markers, AKT and NF-kB, decreased in AgNP-treated cells.”

Chronic accumulation and long-term systemic effects remain insufficiently characterized.

Silver NanoParticles and Magnetic Fields
Summary:
1. “exposure to PMF increased the ability of AgNPs uptake”
2. 6x improvement from AgNPs alone

could glucose capping of SilverNPs work as trojan horse?

Sodium selenite might protect against toxicity of AgNPs in normal cells.

-uncoated AgNPs can degrade the gut microbiome. PVP, citrate, green-synthesized, chitosan coating, may reduce the effect.
Similar oxidative considerations may apply to selenium compounds, though mechanisms differ.
co-ingestion with food (higher pH) favors reduction and lower Ag+ levels.
-action mechanisms of AgNPs: the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure.

AgNP anticancer effects come from three overlapping mechanisms:
-Nanoparticle–cell interaction (uptake, membrane effects)
-Intracellular ROS generation
-Controlled Ag⁺ release inside cancer cells

Comparison adding Citrate Capping
| Property              | Uncapped AgNPs | Citrate-capped AgNPs |
| --------------------- | -------------- | -------------------- |
| Stability             | Poor           | Excellent            |
| Free Ag⁺              | High           | Low                  |
| Normal cell toxicity  | Higher         | Lower                |
| Cancer selectivity    | Lower          | **Higher**           |
| Mechanism specificity | Crude          | **Targeted**         |
| Storage behavior      | Degrades       | Stable               |

Rank Pathway / Target Axis Cancer Cells Normal Cells Primary Effect Notes / Cancer Relevance Ref
1 Oxidative stress / ROS generation ↑ ROS (sustained) ↑ transient ROS → ↓ net ROS after adaptation Upstream cytotoxic trigger AgNP exposure commonly elevates ROS in cancer cells, initiating downstream stress-death programs (ref)
2 Thiol buffering (GSH pool) ↓ GSH (depletion) ↔ or transient ↓ with recovery Loss of redox buffering Colon cancer model: AgNPs induce oxidative cell damage through inhibition/depletion of reduced glutathione with downstream mitochondrial apoptosis (ref)
3 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak ↔ mild inhibition with recovery Bioenergetic destabilization ETC impairment amplifies ROS, precedes ΔΨm loss, and contributes to ATP collapse in cancer cells
4 Mitochondrial integrity (ΔΨm / MMP) ↓ ΔΨm ↔ largely preserved Mitochondrial dysfunction Breast cancer model: AgNP exposure dissipates mitochondrial membrane potential during cytotoxic progression (ref)
5 Intrinsic apoptosis (caspase cascade) ↑ caspase-dependent apoptosis ↔ minimal activation Programmed cell death Colon cancer model: “silver-based nanoparticles” induce apoptosis mediated through p53 (apoptosis direction shown) (ref)
6 Genotoxic stress / DNA damage ↑ DNA damage ↑ damage at high dose with efficient repair Checkpoint/death signaling Study documents AgNP-mediated DNA damage; susceptibility increases with impaired DNA repair capacity (ref)
7 ER stress / UPR (CHOP-dependent) ↑ ER stress → apoptosis ↑ adaptive UPR (no CHOP) Proteotoxic stress signaling Breast cancer cells: AgNPs induce “irremediable” ER stress leading to UPR-dependent apoptosis (ref)
8 Autophagy program ↑ autophagy (protective) ↑ adaptive autophagy Stress adaptation AgNPs induce autophagy in cancer cells; inhibiting autophagy enhances AgNP anticancer killing (ref)
9 Autophagic flux / lysosomal function ↓ flux (lysosomal defect) ↔ preserved flux Autophagic failure AgNP-induced lysosomal dysfunction drives autophagic flux defects (LC3-II accumulation) (ref)
10 NRF2 antioxidant response ↔ insufficient activation ↑ NRF2 activation Adaptive redox defense NRF2 activation in normal cells restores GSH and antioxidant enzymes, limiting toxicity
11 Stress MAPK (p38) / checkpoint signaling ↑ p38 → arrest/apoptosis ↑ transient p38 → recovery Stress signaling Jurkat T-cell model shows p38 MAPK activation with DNA damage and apoptosis (ref)
12 Angiogenesis / invasion (VEGF, NF-κB-linked) ↓ angiogenesis / ↓ invasion ↔ minimal effect Anti-angiogenic / anti-invasive AgNPs inhibit VEGF-induced permeability and invasion in tumor models (ref)


selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability
Scientific Papers found: Click to Expand⟱
4551- AgNPs,  Fenb,    Ångstrom-Scale Silver Particles as a Promising Agent for Low-Toxicity Broad-Spectrum Potent Anticancer Therapy
- in-vivo, Lung, NA
eff↑, eff↑, Apoptosis↑, selectivity↓, TumCG↓,
4433- AgNPs,    Advancements in metal and metal oxide nanoparticles for targeted cancer therapy and imaging: Mechanisms, applications, and safety concerns
- in-vitro, Liver, HepG2 - in-vitro, Nor, L02
selectivity↑, selectivity↓, mt-ROS↑,
4393- AgNPs,    Nanotoxic Effects of Silver Nanoparticles on Normal HEK-293 Cells in Comparison to Cancerous HeLa Cell Line
- in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293
selectivity↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

mt-ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 2,   selectivity↓, 3,   selectivity↑, 1,  
Total Targets: 6

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: selectivity, selectivity
3 Silver-NanoParticles
1 Fenbendazole
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:153  Target#:1110  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page